NYSE$HIMS
Hims & Hers Health Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Hims & Hers reported record growth in revenue, net income, and adjusted EBITDA in Q1 2025.
Hims & Hers delivered exceptional financial performance in Q1 2025, more than doubling revenue year-over-year and significantly increasing profitability across key metrics, driven by personalized treatments and expansion in weight loss solutions.
- Revenue grew 111% year-over-year to $586 million.
- Net income increased to $49.5 million from $11.1 million a year ago.
- Adjusted EBITDA surged to $91 million, up 182% year-over-year.
- Subscriber base expanded to 2.4 million, up 38% year-over-year.
Headline financials
Revenue & EPS history
Hims & Hers · Revenue · Quarterly
$586M
Revenue by segment
Hims & Hers · $227M total across 2 segments · Q3 2023
- Online Revenue$220M+57.1%96.9%
- Wholesale Revenue$7.03M+39.1%3.1%
Forward guidance
Hims & Hers projects FY2025 revenue of $2.3–$2.4B and adjusted EBITDA of $295–$335M, supported by ongoing subscriber growth and product expansion.
Tailwinds
- Forecasts >65% YoY growth in Q2 revenue.
- Raised 2025 Adjusted EBITDA guidance to $295–$335M.
- Continued expansion in GLP-1 and personalized treatment offerings.
- New partnership with Novo Nordisk to offer Wegovy.
- Launch of at-home lab testing and plans to enter hormone therapy market.
Headwinds
- Gross margin declined by ~900 bps YoY to 73%.
- Ongoing semaglutide transition may affect near-term weight loss revenue.
- Shift in sexual health strategy slowed new customer growth.
- High marketing expenses including Super Bowl ad.
- Inventory levels increased significantly YoY.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+2.5%
Avg return
Earnings day
+3.8%
Avg return
5 days after
+12.2%
Avg return
30 days after
50%
13 / 26 earnings
Positive
+41.1%
Q4 2023
Best reaction
-22.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.0% | -11.4% | — | |
| Q4 2025 | -2.8% | -6.4% | +34.5% | |
| Q3 2025 | -3.6% | -7.6% | -9.8% | |
| Q1 2025 | +18.5% | +24.1% | +26.0% | |
| Q4 2024 | -22.3% | -12.1% | -37.8% | |
| Q3 2024 | +1.4% | +15.0% | +66.6% | |
| Q2 2024 | -4.0% | -9.2% | -16.9% | |
| Q1 2024 | +9.7% | +9.1% | +93.2% | |
| Q4 2023 | +41.1% | +37.8% | +65.3% | |
| Q3 2023 | +7.6% | +5.1% | +37.3% | |
| Q2 2023 | -8.7% | -11.7% | -15.2% | |
| Q1 2023 | -11.5% | -10.2% | -23.9% | |
| Q4 2022 | +15.4% | +6.0% | +2.7% | |
| Q3 2022 | +30.1% | +37.2% | +64.7% | |
| Q2 2022 | -3.4% | +9.2% | -0.6% | |
| Q1 2022 | -13.0% | -13.5% | +5.3% | |
| Q4 2021 | +8.0% | +20.5% | +19.8% | |
| Q3 2021 | -7.0% | -1.3% | -26.3% | |
| Q2 2021 | +7.0% | -4.7% | +11.1% | |
| Q1 2021 | +13.7% | +44.9% | +33.1% | |
| Q2 2020 | -8.4% | -7.2% | -21.9% | |
| Q4 2020 | -7.5% | -15.4% | -21.3% | |
| Q3 2020 | +0.1% | +0.0% | +17.5% | |
| Q1 2020 | -0.7% | -0.5% | +0.1% | |
| Q4 2019 | +1.4% | +2.1% | +2.2% | |
| Q3 2019 | +0.0% | +0.3% | -0.6% | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro